^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Loqtorzi (toripalimab-tpzi)

    i
    Other names: JS001, JS-001, JS 001, TAB-001, TAB001, terepril monoclonal antibody, treipril monoclonal antibody, TAB 001
    Company:
    Apotex, Coherus Oncology, Dr. Reddy’s, Excellmab, Hikma, LEO Pharma, Shanghai Junshi Biosci
    Drug class:
    PD1 inhibitor
    Related drugs:
    3d
    Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) (clinicaltrials.gov)
    P2, N=24, Recruiting, Stanford University | Trial completion date: Dec 2027 --> Jan 2029 | Trial primary completion date: Dec 2025 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi) • capecitabine
    7d
    Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Chicago | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • paclitaxel • Loqtorzi (toripalimab-tpzi)
    7d
    A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment (clinicaltrials.gov)
    P3, N=440, Not yet recruiting, Shanghai Jiatan Pharmatech Co., Ltd
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PIK3CA mutation
    |
    Loqtorzi (toripalimab-tpzi)
    7d
    A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=228, Recruiting, Advenchen Laboratories, LLC
    New P1/2 trial
    |
    Loqtorzi (toripalimab-tpzi)
    8d
    Complete response to BRICS in Locally advanced pancreatic cancer (pMMR, CPS 30): a case report. (PubMed, Front Immunol)
    In this case, the treatment comprised SBRT 24 Gy/3 fractions → q21d toripalimab 240 mg + nab-paclitaxel 200→100 mg + anlotinib 12 mg d1-14, with continuous Bifidobacterium triple viable tablets. These results challenge the prevailing assumption that pMMR status invariably predicts resistance to immunotherapy. These findings suggest that, in pMMR pancreatic cancers with high PD-L1 CPS, multimodal treatment strategies may remodel the tumor microenvironment and overcome immune resistance, highlighting a promising therapeutic direction.
    Journal • PD(L)-1 Biomarker • IO biomarker • pMMR
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    8d
    Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=198, Not yet recruiting, Fujian Cancer Hospital
    New P2 trial • Checkpoint inhibition
    |
    Loqtorzi (toripalimab-tpzi)
    9d
    HCB101-201: Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=500, Active, not recruiting, FBD Biologics Limited | Recruiting --> Active, not recruiting | N=150 --> 500
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • carboplatin • 5-fluorouracil • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Loqtorzi (toripalimab-tpzi) • capecitabine • albumin-bound paclitaxel • Cyramza (ramucirumab) • oxaliplatin • etoposide IV • irinotecan • leucovorin calcium • HCB101
    9d
    Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy (clinicaltrials.gov)
    P2, N=170, Terminated, Sun Yat-sen University | Recruiting --> Terminated; Since the interim results of the ADRIATIC trial presented at the ASCO Annual Meeting in June 2024, the design of the control group is no longer consistent with current clinical practice.
    Trial termination
    |
    Loqtorzi (toripalimab-tpzi)
    10d
    A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=392, Active, not recruiting, LaNova Medicines Limited | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Loqtorzi (toripalimab-tpzi) • cafelkibart (LM-108)
    10d
    Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08) (clinicaltrials.gov)
    P2, N=111, Recruiting, First Affiliated Hospital of Zhejiang University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • HR positive
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Herceptin (trastuzumab) • paclitaxel • Loqtorzi (toripalimab-tpzi) • cyclophosphamide • epirubicin • trastuzumab rezetecan (SHR-A1811)
    11d
    Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Sun Yat-sen University
    New P2 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • epirubicin